Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1018
Community First: Practical Strategies for Inclusive Implementation Science
Join The Choice Agenda and Hunter College’s Dr. Sarit Golub for a participatory discussion on implementation science – including opportunities, pitfalls and ways in which community leadership – beyond perfunctory...
The Future Won’t Build Itself: Sustaining the Movement CASPR Started
Join AVAC and partners as we launch the CASPR Impact Report, detailing the achievements of the Coalition to Accelerate & Support Prevention Research (CASPR) over the course of 8+ years. We will share these wins, discuss lessons for the field and...
CROI 2025 Cure Reflections Video Series
A PAVE (Pediatric Adolescent Virus Elimination) and REACH video series with HIV cure-related takeaways from CROI 2025.
Prevention Option:
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
Source of Lenacapavir for PrEP Supply to Early Adopter Countries
The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.
Prevention Option:
Speeding Up Access to PrEP
The timeline for hitting key milestones in product introduction is moving faster for injectable LEN than for any previous PrEP products, starting from the announcement of efficacy results in Phase III trials. LEN’s accelerated timeline compared to oral PrEP, DVR, and CAB reflects a field-wide effort to learn lessons from previous PrEP rollout and not repeat the mistakes of the past.
Prevention Option:
Advocates’ Primer: Understanding Bioequivalence and Pharmacokinetic Studies in Next-Generation HIV Prevention Products
As more next-generation PrEP options become available, HIV prevention research is shifting away from large, multi-year efficacy trials toward pharmacokinetic (PK) and bioequivalence (BE) studies — which test whether a new formulation behaves in the body like a product already proven to work. This primer explains the shift and what it means for advocates.
Prevention Option:
An Advocates’ Checklist for Lenacapavir for PrEP Introduction
The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers accelerate equitable access to LEN for PrEP. The checklist is designed to support faster, community-centered rollout ahead of broader generic availability in 2027.
Prevention Option:
What Does It Take to Conduct HIV Cure Research?
Progress towards an HIV cure depends on strengthening four critical systems: lab equipment, sustainable funding, policy & programs, and training.
Prevention Option:
Lenacapavir Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of May 2026.
Prevention Option:
showing 1-10 of 1018